Non-Hodgkin lymphomas are closely related diseases, each involving the malignant transformation of lymphoid cells. The molecular pathogenic mechanisms underlying the complex process of lymphomagenesis in NHL have been found to be due to genetic aberrations including activation of proto-oncogenes (BCL1, BCL2, BCL6 and C-MYC), inactivation of tumor suppressor genes such as TP53 and retinoblastoma (Rb) genes. The aim of the current study was to clarify the impact of BCL2 and BCL6 expression on the clinical and laboratory characteristics of B-cell NHL cases and to rule out their possible role as prognostic markers for B-cell NHL. The study included 61 NHL patients. Bcl-2 and Bcl-6 expression was examined by immunohistochemical staining. BCL-2 expression was detected in 35/61(57.4%) of NHL patients.BCL-6 expression was detected in 6/61(9.8%) of NHL patients. There was no statistical significant difference between B-NHL with or without BCL-6 expression as regards their clinical and laboratory data. There was no statistical significant difference between B-NHL with or without BCL-2 expression as regards their clinical and laboratory data except that BCL-2 was more expressed in cases with hypercellular marrow.